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Critical roles for the 
phosphatidylinositide 3-kinase 
isoforms p110β and p110γ in 
thrombopoietin-mediated priming 
of platelet function
samantha F. Moore  1, Nina R. smith1, thomas A. Blair1,2, tom N. Durrant1 & Ingeborg Hers1
Thrombopoietin (TPO) enhances platelet activation through activation of the tyrosine kinase; JAK2 
and the lipid kinase phosphatidylinositide 3-kinase (PI3K). The aim of our study was to identify the 
PI3K isoforms involved in mediating the effect of TPO on platelet function and elucidate the underlying 
mechanism. We found that p110β plays an essential role in TPO-mediated (i) priming of protease-
activated receptor (PAR)-mediated integrin αIIbβ3 activation and α-granule secretion, (ii) synergistic 
enhancement of PAR-mediated activation of the small GTPase RAP1, a regulator of integrin activation 
and (iii) phosphorylation of the PI3K effector Akt. More importantly, the synergistic effect of TPO on 
phosphorylation of extracellular-regulated kinase (ERK1/2) and thromboxane (TxA2) synthesis was 
dependent on both p110β and p110γ. p110β inhibition/deletion, or inhibition of p110γ, resulted in 
a partial reduction, whereas inhibiting both p110β and p110γ completely prevented the synergistic 
effect of TPO on ERK1/2 phosphorylation and TxA2 synthesis. The latter was ablated by inhibition of 
MEK, but not p38, confirming a role for ERK1/2 in regulating TPO-mediated increases in TxA2 synthesis. 
In conclusion, the synergistic effect of TPO on RAP1 and integrin activation is largely mediated by 
p110β, whereas p110β and p110γ contribute to the effect of TPO on ERK1/2 phosphorylation and TxA2 
formation.
The endogenous myeloproliferative leukaemia protein (c-MPL) agonist; thrombopoietin (TPO) is a cytokine 
primarily involved in regulating platelet production, but it can also act as a platelet primer by enhancing platelet 
activation and function1–3. This cytokine can therefore play a pro-thrombotic and potentially pathogenic role 
in clinical conditions where it is found to be elevated. These conditions include altered bone marrow haemato-
poiesis/failure4,5, coronary artery disease6, acute angina7, sepsis8, inflammatory bowel disease9, burns patients10 
and smokers11. Furthermore, TPO mimetics are used in the clinic to treat primary immune thrombocytopenia. 
These mimetics could potentially alter/restore platelet function causing either beneficial or detrimental effects 
not associated with the increase in platelet count, however information on this is still scarce and conflicting12. We 
and others have previously demonstrated that the mechanism by which TPO can enhance platelet activation is 
dependent on the activation of both the non-receptor tyrosine kinase janus kinase 2 (JAK2) and the lipid kinase 
phosphatidylinositide 3-kinase (PI3K)1,13.
Agonist-mediated activation of PI3K leads to the production of the second messenger molecule phosphatidy-
linositol (3,4,5)-trisphosphate (PIP3) and is well established in playing a vital role in supporting platelet activation 
and thrombus formation. The class I PI3Ks of which there are four catalytic isoforms; are responsible for the 
production of PIP3. All four of these isoforms are expressed in platelets with the p110β isoform being the most 
abundant and p110δ the least (β > γ > α > δ, based on the copy number analyses)14,15. The p110β isoform has been 
robustly demonstrated to play a dominant role in regulating platelet function through use of pharmacological 
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agents and genetic models. The deletion of the p110β isoform or expression of a kinase dead form results in near 
ablation of both thrombin and convulxin-mediated production of PIP3 and in the phosphorylation of the PI3K 
effector Akt in response to thrombin, convulxin, collagen, adenosine diphosphate (ADP) and the TxA2 analogue 
U4661916,17. Furthermore, p110β has been demonstrated to support platelet function and thrombus formation 
after arterial injury but is not involved in regulating the haemostatic response16. In contrast, more minor roles 
have been reported for the other isoforms. The p110γ isoform appears to be primarily involved in regulating 
platelet response to ADP, with platelets deficient in p110γ having impaired aggregation in response to ADP and 
ablated ADP-mediated Akt phosphorylation18,19. The p110δ isoform plays a minor functional role in signalling 
downstream of GPVI and integrin αIIbβ320, whereas the p110α isoform has an unusual role in regulating the abil-
ity of platelet priming agents to enhance platelet function21–24.
The aim of this study was to investigate which PI3K isoforms can contribute to the priming effect of TPO 
on platelet function using a combination of pharmacological inhibitors and genetic mouse models. Here we 
demonstrate that the priming effect of TPO on integrin αIIbβ3 activation and α-granule secretion is primarily 
mediated through the PI3K isoform p110β and involves the synergistic activation of the small GTPase RAP1. 
Furthermore, we have evidence that TPO/c-MPL in platelets can signal through the PI3K isoform p110γ; an 
isoform more commonly associated with being activated downstream of G-protein-coupled receptors (GPCR). 
Activation of this isoform in combination with p110β by TPO, is a requirement for the synergistic activation of 
the mitogen-activated protein kinase (MAPK) extracellular signal–regulated kinase (ERK1/2) and subsequent 
priming of TxA2 production.
Results
Thrombopoietin enhances platelet function through PI3-kinase. To confirm that TPO increases 
platelet function in a PI3K-dependent manner, we examined PAR-mediated (SFLLRN) integrin αIIbβ3 activa-
tion and α-granule secretion in washed platelets pre-treated with TPO in the absence and presence of the pan-
PI3K inhibitor wortmannin. TPO markedly enhanced PAR-mediated integrin αIIbβ3 activation, resulting in a 
left-shift of the concentration-response curve (pEC50 = 5.73 ± 0.1 to 5.90 ± 0.1, n = 4 ± s.e.m) and an increase 
in maximal integrin activation (Fig. 1a, Supplementary Fig. S1). TPO also induced alterations in PAR-mediated 
α-granule secretion, as measured by P-selectin exposure (Fig. 1b, Supplementary Fig. S1). The effect of TPO on 
α-granule secretion was muted compared to the effect on integrin αIIbβ3 activation, the curve was left-shifted 
(pEC50 = 5.66 ± 0.08 to 5.79 ± 0.07, n = 3 ± s.e.m), but maximal P-selectin exposure was unaltered. Wortmannin 
treatment reduced maximal PAR-mediated integrin activation by ~40%, whereas α-granule secretion was mini-
mally affected. Furthermore, the priming effects of TPO on both integrin αIIbβ3 activation and α-granule secre-
tion were prevented by pre-treating platelets with wortmannin (Fig. 1a,b). These results are in agreement with 
previous findings13,25,26.
Enhancement of integrin αIIbβ3 activation and α-granule secretion are dependent on p110β. 
The class IA PI3K isoforms (catalytic subunits; p110α, β and δ) are known to be activated downstream of 
tyrosine-kinase associated receptors via the recruitment of p85–p110 complexes and relief of p85 inhibition on 
the p110 catalytic subunits. Of these isoforms p110β is the most abundant14,15 in platelets and has been demon-
strated to play an integral role in platelet activation27 and in supporting platelet priming in combination with the 
p110α isoform21,24. Pre-treatment of platelets with the p110β inhibitor TGX-221 had a similar effect as wortman-
nin on integrin αIIbβ3 activation and α-granule secretion (Fig. 1c,d). Maximal PAR-mediated integrin αIIbβ3 acti-
vation was reduced by ~30%, whereas α-granule secretion was unaltered; results in line with previous findings28. 
Furthermore, TGX-221 suppressed TPO-mediated enhancement of integrin αIIbβ3 activation and α-granule 
secretion (Fig. 1c,d). In the presence of TGX-221, TPO failed to left-shift PAR-mediated integrin αIIbβ3 activation 
(pEC50 = 5.66 ± 0.06 to 5.69 ± 0.06, n =8  ± s.e.m) or α-granule secretion (pEC50 = 5.60 ± 0.06 to 5.60 ± 0.06, 
n = 8 ± s.e.m) or increase maximal integrin activation.
To strengthen these findings, we aimed to determine the effect of genetic deletion of p110β on the priming 
effect of TPO on PAR-mediated integrin activation. As platelets are anucleate cells not easily amenable to genetic 
manipulation we employed the use of a transgenic mouse where p110β is knocked-out. We determined that TPO 
enhanced platelet functional responses in wild-type control mouse platelets (mixed C57BL/6J × 129 Sv) elicited 
by sub-maximal concentrations of the PAR-4 selective agonist; AYPGKF (in mouse platelets in contrast to human 
platelets, PAR-4 is the dominant thrombin receptor). Interestingly, functional responses in mouse platelets com-
pared to human appeared to be more susceptible to enhancement by TPO. However, in support of our findings in 
human platelets, this enhancement was suppressed in platelets deficient in the p110β isoform (Fig. 2a,b). Similar 
but not identical findings were obtained when wild-type mouse platelets (C57/BL6) were treated with TGX-221 
(Fig. 2c,d). Interestingly, TPO was still able to significantly enhance integrin αIIbβ3 activation (Supplementary 
Fig. S1) in human platelets in the presence of PI3K isoform selective inhibitors for p110α, p110δ and p110γ, and 
in p110α-deficient mouse platelets21 (Supplementary Fig. S2). Together these results demonstrate that in human 
and mouse platelets p110β is the dominant PI3K isoform involved in regulating the priming effect of TPO.
p110β regulates the ability of TPO to synergistically enhance RAP1 activation. The small 
G-protein RAP1 is a well-established critical common regulator of platelet function, with the deletion of the 
predominate isoform; Rap1b, resulting in impaired integrin αIIbβ3 activation and granule secretion29,30. Here we 
demonstrate that TPO mediates a synergistic enhancement in RAP1 activation. Stimulation of platelets with a 
sub-maximal concentration of SFLLRN induced RAP1 guanosine-5′-triphosphate (GTP) loading above basal 
whereas TPO alone did not (Fig. 3a). Interestingly, SFLLRN in the presence of TPO resulted in a strong syner-
gistic enhancement in RAP1 activation, with the combined action of TPO and SFLLRN stimulating a stronger 
response than the sum of their effects (Fig. 3a). In line with our findings from platelet activation, the generic PI3K 
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inhibitor wortmannin (Fig. 3b) and the p110β inhibitor TGX-221 (Fig. 3b,c) blocked the synergistic enhancement 
in RAP1 activation. Although the interpretation of the wortmannin data may be confounded by the absence of 
RAP1 activation by SFLLRN alone, this was not the case for TGX-221 where SFLLRN-mediated RAP1 activation 
was still detectable (p < 0.01, n = 9). Together, this data therefore suggests that TPO enhances integrin αIIbβ3 acti-
vation and α-granule secretion through p110β-mediated increases in RAP1 activation.
A role for p110β in regulating TPO-mediated enhancement of PAR-mediated signalling events. 
The enhancement in platelet functional responses occurred with a concurrent enhancement in the activation of 
multiple signalling pathways (Fig. 4a). In line with previous findings, TPO induced the phosphorylation of the 
Figure 1. Enhancement of platelet function by TPO is supressed by the pan-PI3K inhibitor wortmannin and 
the p110β selective inhibitor TGX-221. (a) SFLLRN-mediated integrin αIIbβ3 activation was enhanced by 
TPO (100 ng/ml, 5 min), resulting in a left shift of the curve (pEC50 = 5.73 ± 0.1 to 5.90 ± 0.1, n = 4 ± s.e.m, 
p < 0.001) and an increase in the maximal response (p < 0.01). Pre-incubation of platelets with the pan-
PI3K inhibitor wortmannin (WTM) ablated the left shift in the curve (pEC50 = 5.72 ± 0.09 to 5.77 ± 0.09, 
n = 4 ± s.e.m, p > 0.05) and the increase in the maximal response (p > 0.05). (b) SFLLRN-mediated α-granule 
secretion (P-selectin exposure) was moderately enhanced by TPO (100 ng/ml, 5 min), resulting in a left shift 
of the curve (pEC50 = 5.66 ± 0.08 to 5.79 ± 0.07, n = 3 ± s.e.m, p < 0.05) but not an increase in the maximal 
response (p > 0.05). Pre-incubation with WTM ablated the left shift in the curve (pEC50 = 5.60 ± 0.07 to 
5.64 ± 0.07, n = 3 ± s.e.m, p > 0.05). (c) SFLLRN-mediated integrin αIIbβ3 activation was enhanced by TPO 
(100 ng/ml, 5 min), resulting in a left shift of the curve (pEC50 = 5.71 ± 0.06 to 5.80 ± 0.07 n = 8 ± s.e.m, 
p < 0.001) and an increase in the maximal response (p < 0.001). Pre-incubation of platelets with the PI3K 
p110β selective inhibitor TGX-221 (200 nM, 15 min) ablated the left shift in the curve (pEC50 = 5.66 ± 0.06 
to 5.69 ± 0.06, n = 8 ± s.e.m, p > 0.05) and the increase in the maximal response (p > 0.05). (d) SFLLRN-
mediated α-granule secretion (P-selectin exposure) was moderately enhanced by TPO (100 ng/ml, 5 min), 
resulting in a left shift of the curve (pEC50 = 5.60 ± 0.06 to 5.70 ± 0.06, n = 8 ± s.e.m, p < 0.01) but not an 
increase in the maximal response (p > 0.05). Pre-incubation with TGX-221 ablated the left shift in the curve 
(pEC50 = 5.60 ± 0.06 to 5.60 ± 0.06, n = 8 ± s.e.m, p > 0.05). Curves were fitted for each individual donor and 
curve parameters calculated using a four-parameter logistic equation (GraphPad Prism 7.0). For displayed 
graphs, concentration-response curves from different donors were pooled after normalising them to the 
maximal response (curve top) obtained in the vehicle-control samples. Statistical testing of curve parameters 
was performed using 2-way ANOVAs with Bonferroni’s multiple comparisons test: (Variable 1 = TPO, Variable 
2 = Inhibitor). Significance was determined when p < 0.05.
www.nature.com/scientificreports/
4Scientific RepoRts |          (2019) 9:1468  | https://doi.org/10.1038/s41598-018-37012-9
PI3K effector Akt and enhanced the phosphorylation of Akt induced by sub-maximal concentrations of SFLLRN 
(Fig. 4a,b). Akt phosphorylation by TPO alone or the combination of TPO and SFLLRN was almost ablated by 
the p110β inhibitor TGX-221. In contrast, TPO was unable to stimulate phosphorylation of the classical MAP 
kinases ERK1/2 but induced a striking synergistic enhancement of SFLLRN-mediated ERK1/2 phosphoryla-
tion (Fig. 4a,c). This synergistic enhancement was reduced but not abolished by TGX-221. SFLLRN-mediated 
phosphorylation of p38 and its substrate MAPKAPK-2 was subtlety increased in the presence of TPO, however 
this did not reach significance and was not altered by TGX-221 (Fig. 4a,d). Similar results were obtained using 
p110β-deficient platelets and mouse platelets pre-treated with TGX-221 (Supplementary Fig. S3).
Synergistic phosphorylation of ERK1/2 is mediated by p110β and p110γ. It was noted that phar-
macological inhibition (Fig. 4a,c, Supplementary Fig. S1) or deletion of p110β (Supplementary Fig. S1) did not 
abolish the synergistic effect of TPO on ERK1/2 phosphorylation. Therefore, we speculated that an additional 
PI3K isoform may be involved in regulating this effect. Indeed, we found that pre-treatment of platelets with the 
p110γ inhibitor AS252424 resulted in a reduction of the synergistic effect of TPO on ERK1/2 phosphorylation 
(Fig. 5a,c). Furthermore, the combination of TGX-221 and AS252424 reduced ERK1/2 phosphorylation further 
than pre-treatment with TGX-221 alone (Fig. 5a,c), leaving little residual ERK1/2 phosphorylation. The latter 
may be independent of PI3K as pre-treatment of platelets with the PI3K inhibitor wortmannin reduced ERK1/2 
phosphorylation to similar levels (Supplementary Fig. S3). These results demonstrate that both p110β and p110γ 
contribute to the synergistic effect of TPO on PAR-mediated ERK1/2 phosphorylation.
Figure 2. Enhancement of mouse platelet function by TPO is supressed by either deletion or inhibition of 
PI3K p110β. (a) AYPGKF-mediated integrin αIIbβ3 activation (n = 3 ± s.e.m) and (b) α-granule secretion was 
enhanced by TPO (100 ng/ml, 5 min) in platelets from wild-type control (WT, mixed C57BL/6J × 129 Sv) mice. 
This enhancement was markedly reduced in platelets from p110β knock-out (KO) mice. Similarly, (c) AYPGKF-
mediated integrin αIIbβ3 activation (n = 3 ± s.e.m) and (d) α-granule secretion was enhanced by TPO (100 ng/
ml, 5 min) in platelets from wild-type (WT, C57BL/6J) mice in the absence but not presence of the PI3K p110β 
selective inhibitor TGX-221 (200 nM, 15 min). Data from individual experiments was pooled after normalising 
them to a maximum response evoked in an independent sample (wild-type/vehicle treated platelets stimulated 
with 0.1 U/mL thrombin). 2-way ANOVAs were performed with Bonferroni’s multiple comparisons test: 
(*Variable 1 = AYPGKF concentration, Variable 2 = TPO or †Variable 1 = AYPGKF concentration, Variable 
2 = Genotype/Inhibitor). Significance was determined when p < 0.05, *p < 0.05, **p < 0.01, ***p < 0.001.
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Synergistic activation of ERK1/2 results in enhanced TxA2 generation. ERK1/2 has previ-
ously been implicated in regulating the ability of TPO to prime platelet function via a TxA2-dependent path-
way3,31. We therefore sought to confirm whether TPO can enhance TxA2 generation and if this enhancement 
Figure 3. Critical role for PI3K p110β in the synergistic activation of the small GTPase RAP1. Washed 
human platelets were pre-incubated with TPO (100 ng/ml) for 5 min before stimulation with SFLLRN (1 μM, 
5 min) in the absence or presence of indicated PI3K inhibitors. Platelets were lysed in RAP1 lysis buffer and 
incubated with the GST-tagged Rap binding domain of RAPGDS (GST-RALGDS-RBD), which specifically 
precipitates the active GTP-bound form of RAP1. Active RAP1 was identified by immunoblotting with an 
anti-RAP1 antibody. Matching whole cell lysates were run on different gels to determine the total amount of 
RAP1 (active and inactive) present. LI-COR® Image Studio (LI-COR®, Cambridge, UK) was used to create 
final images and to quantify bands as outlined in the Material and Methods. Full images and molecular 
weights from these experiments are presented in Supplementary Fig. S5. (a) Immunoblotting determined that 
TPO can synergistically enhance GTP loading of RAP1, with the combined action of TPO and SFLLRN on 
mediating RAP1 GTP loading being stronger than the sum of their effects (n = 9 ± s.e.m), 2-way ANOVA was 
performed with Bonferroni’s multiple comparisons test: (Variable 1 = SFLLRN, Variable 2 = TPO). (b) Pre-
treatment of platelets with the pan PI3K inhibitor wortmannin (100 nM, 15 min) ablated the increase in RAP1-
GTP (n = 4 ± s.e.m), 2-way ANOVA was performed with Bonferroni’s multiple comparisons test: (Variable 
1 = SFLLRN, Variable 2 = WTM). (c) Furthermore, pre-treatment of platelets with the p110β inhibitor TGX-
221 (200 nM, 15 min) also ablated the increase in RAP1-GTP (n = 9 ± s.e.m). 2-way ANOVA was performed 
with Bonferroni’s multiple comparisons test: (Variable 1 = SFLLRN, Variable 2 = TGX-221). Significance was 
determined when p < 0.05, *p < 0.05, **p < 0.01, ***p < 0.001.
www.nature.com/scientificreports/
6Scientific RepoRts |          (2019) 9:1468  | https://doi.org/10.1038/s41598-018-37012-9
is blocked under conditions where ERK1/2 phosphorylation is also attenuated. We confirmed that despite the 
inability of TPO to stimulate TxA2 generation by itself, it enhanced PAR-mediated TxA2 generation (Fig. 6a). 
Furthermore, this enhancement in TxA2 generation was blocked in the presence of the MEK inhibitor PD184352 
but not the p38 inhibitor VX-702 (Fig. 6b). Under the conditions used, these inhibitors selectively blocked 
Figure 4. TPO enhances SFLLRN-mediated signalling events. Washed human platelets were pre-incubated 
with TPO (100 ng/ml) for 5 min before stimulation with SFLLRN (1 μM, 5 min) in the absence or presence of 
the p110β inhibitor TGX-221 (200 nM, 15 min). Platelets were lysed in 4x NuPAGE sample buffer containing 
0.5M DTT and protein phosphorylation analysed by electrophoresis/immunoblotting. Samples were run on 
multiple gels for probing with multiple antibodies. For some experiments, gels and membranes were cut into 
two parts to be probed separately with different primary antibodies (e.g. pJAK2Y1007/1008 and pAktS473, pSTAT5α/
βY694 and pERKT202/Y204). LI-COR® Image Studio (LI-COR®, Cambridge, UK) was used to create final images 
and to quantify bands as outlined in the Material and Methods. Full images and molecular weights from these 
experiments are presented in Supplementary Fig. S6. All samples in the panel figure shown are derived from 
the same donor/experiment. (a) Representative blot demonstrating that TPO can enhance phosphorylation 
of AktS473, ERK1/2T202/Y204, p38T180/Y182 and its substrate MAPKAPK2T334. These enhancements were reduced 
by TGX-221. (b) TPO induces phosphorylation of AktS473 and enhances SFLLRN-mediated phosphorylation. 
TPO-meditated effects on AktS473 phosphorylation were reduced by TGX-221 (n = 9 ± s.e.m). (c) TPO 
did not evoke phosphorylation of ERK1/2T202/Y204 alone, however it induces a synergistic enhancement of 
SFLLRN-mediated phosphorylation which was reduced by TGX-221 (n = 9 ± s.e.m). (d) TPO in the absence 
and presence of TGX-221 induced subtle increases in SFLLRN-mediated phosphorylation of p38T180/Y182 
(n = 5 ± s.e.m). Data are expressed as arbitrary fluorescence units (A.F.U, LI-COR® Image Studio). 2-way 
ANOVAs were performed with Bonferroni’s multiple comparisons test: (*Variable 1 = SFLLRN, Variable 
2 = TPO or †Variable 1 = SFLLRN, Variable 2 = TGX-221). Significance was determined when p < 0.05, 
*p < 0.05, **p < 0.01, ***p < 0.001.
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phosphorylation of ERK1/2 and the p38 substrates MAPKAPK2 and HSP27, respectively (Supplementary 
Fig. S4). We also demonstrate the vital role for PI3K in eliciting the ability of TPO to enhance TxA2 generation as 
pre-treatment of platelets with wortmannin ablated the priming effect of TPO (Fig. 6c). Moreover, pre-treatment 
with either the p110β inhibitor; TGX-221 or the p110γ inhibitor; AS252424 resulted in substantial reductions 
in SFLLRN + TPO-mediated TxA2 generation, with combined treatment largely blocking the effect (Fig. 6d). 
Interestingly, the p110γ inhibitor had a greater inhibitory effect than the p110β inhibitor, indicating that the 
p110γ isoform plays a more dominant role than the p110β isoform in regulating TxA2 generation. These results 
Figure 5. Role for p110γ in regulating the effect of TPO on platelets signalling. Washed human platelets were 
pre-incubated with TPO (100 ng/ml) for 5 min before stimulation with SFLLRN (1 μM, 5 min) in the absence or 
presence of the p110β inhibitor TGX-221 (200 nM, 15 min), p110γ inhibitor AS252424 (2 μM, 15 min) or both 
inhibitors. Platelets were lysed in 4x NuPAGE sample buffer containing 0.5M DTT and protein phosphorylation 
analysed by electrophoresis/immunoblotting. Samples were run on multiple gels for probing with multiple 
antibodies. For some experiments, gels and membranes were cut into two parts to be probed separately with 
different primary antibodies (e.g. pJAK2Y1007/1008 and pAktS473, pSTAT5α/βY694 and pERKT202/Y204). LI-COR® 
Image Studio (LI-COR®, Cambridge, UK) was used to create final images and to quantify bands as outlined 
in the Material and Methods. Full images and molecular weights from these experiments are presented in 
Supplementary Fig. S7. All samples in the panel figure shown are derived from the same donor/experiment. (a) 
Representative blot demonstrating that inhibition of either p110β and/or p110γ alters TPO induced signalling 
events. (b) AS252424 supressed TPO and SFLLRN + TPO induced phosphorylation of AktS473 (n = 4 ± s.e.m). 
(c) AS252424 supressed the synergistic enhancement of ERK1/2T202/Y204 phosphorylation evoked by TPO. 
Furthermore, the suppression of ERK1/2T202/Y204 phosphorylation induced by pre-treating platelets with a 
combination of TGX-221 and AS252424 was greater than pre-treatment with TGX-221 alone (n = 4 ± s.e.m). 
(d) AS252424 alone did not alter phosphorylation of p38T180/Y182, however in combination with TGX-221 
suppression of p38 phosphorylation induced by SFLLRN + TPO was observed (n = 5 ± s.e.m). Data are 
expressed as arbitrary fluorescence units (A.F.U, LI-COR® Image Studio). 2-way ANOVAs were performed with 
Bonferroni’s multiple comparisons test: (*Variable 1 = Stimulation, Variable 2 = Inhibitor). Significance was 
determined when p < 0.05, *p < 0.05, **p < 0.01, ***p < 0.001.
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demonstrate an important role for p110β and p110γ in the synergistic effect of TPO on PAR-1 mediated ERK1/2 
phosphorylation and thromboxane synthesis.
ERK1/2 activation is important for the priming effect of TPO under conditions dependent on 
txA2 generation. Our platelet functional studies were performed under conditions where TxA2 generation 
is inhibited (indomethacin-treated); demonstrating that TPO can enhance platelet function independently on 
TxA2 generation. However, previous studies have demonstrated that TPO can also enhance secondary aggrega-
tion and this is blocked by acetylsalicylic acid/aspirin3. We therefore hypothesised that in the absence of indo-
methacin, TPO-mediated enhancement of secondary platelet aggregation would be inhibited by PD184352. 
Indeed, when using sub-threshold concentrations of SFLLRN, TPO mediated two distinct waves of aggregation 
with the secondary but not primary wave being blocked by PD184352 (Fig. 6e).
Figure 6. Role for ERK1/2 and PI3K in regulating TPO-induced increases in TxA2 generation. Human 
platelets (no indomethacin) were pre-incubated with TPO (100 ng/ml) for 5 min before stimulation with 
SFLLRN (1 μM, 5 min) in the absence or presence of the either the p38 inhibitor VX-702 (300 nM, 15 min), 
the MEK inhibitor PD184352 (300 nM, 15 min), the PI3K inhibitor wortmannin (100 nM, 15 min), the p110β 
inhibitor TGX-221 (200 nM, 15 min), the p110γ inhibitor AS242525 (2 μM, 15 min) or a combination of 
TGX-221 and AS242525. Supernatants were collected and TxB2 concentrations assessed using a colorimetric 
ELISA kit. (a) TPO synergistically enhanced PAR-mediated TxB2 production (n = 5 ± s.e.m). 2-way ANOVAs 
were performed with Bonferroni’s multiple comparisons test: (*Variable 1 = SFLLRN, Variable 2 = TPO). 
(b) This enhancement was supressed by the MEK inhibitor PD184352 but not the p38 inhibitor VX-702 
(n = 3 ± s.e.m). 2-way ANOVAs were performed with Bonferroni’s multiple comparisons test: (*Variable 
1 = Stimulation, Variable 2 = Inhibitor). (c) Furthermore, the enhancement in TxB2 production was dependent 
on PI3K as the pan-PI3K inhibitor wortmannin ablated the synergistic increase in TxB2 production evoked by 
SFLLRN and TPO (n = 7 ± s.e.m). 2-way ANOVAs were performed with Bonferroni’s multiple comparisons 
test: (*Variable 1 = Stimulation, Variable 2 = Inhibitor). (d) Both the p110β and p110γ PI3K isoforms were 
observed to contribute to TPO-mediated enhancements in TxB2 production. Both TGX-221 and AS252424 
reduced TxB2 production and pre-treatment of platelets with both inhibitors resulted in further suppression 
of TxB2 production (n = 3 ± s.e.m). 2-way ANOVAs were performed with Bonferroni’s multiple comparisons 
test: (*Variable 1 = Stimulation, Variable 2 = Inhibitor). (e) Representative aggregation traces demonstrate 
that PD184352 can inhibit the secondary but not primary wave of aggregation induced by SFLLRN + TPO. 
Aggregation traces are representative of three independent experiments. Significance was determined when 
p < 0.05, *p < 0.05, **p < 0.01, ***p < 0.001.
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Discussion
This is the first study to demonstrate critical roles for the PI3K isoforms p110β and p110γ in supporting platelet 
priming by TPO. Using both pharmacological tools and genetic models we have found that p110β is the predom-
inant PI3K isoform involved in mediating the priming effect of TPO on PAR-mediated integrin αIIbβ3 activation 
and α-granule secretion, and the concurrent synergistic activation of RAP1 (Fig. 7). Furthermore, both p110β 
and p110γ play an essential role in the synergistic enhancement of PAR-mediated ERK1/2 phosphorylation and 
TxA2 synthesis (Fig. 7).
This and previous studies have demonstrated that TPO alone is unable to induce platelet functional responses, 
however when used in combination with other platelet agonists it can enhance aggregation, integrin αIIbβ3 acti-
vation, granule secretion, TxA2 production and thrombus formation32. This is found to coincide with increases 
in the activation of pathways associated with both PI3K and MAPK signalling. In platelets binding of TPO to its 
receptor; c-MPL will elicit the activation of JAK2 ultimately leading to recruitment and tyrosine phosphorylation 
of SH2 domain containing STATs (signal transducer and activator of transcription) e.g. STAT3 and STAT5α/β33,34. 
Another event that occurs is the tyrosine phosphorylation of the p85 regulatory subunit of PI3K and its associa-
tion with Gab1. This phosphorylation of p85 relieves its inhibitory activity on the p110 catalytic subunits resulting 
in an increase in PI3K activity and the phosphorylation of downstream effectors such as Akt. It is this increase in 
PI3K activity that is a key driver in enhancing PAR-mediated integrin activation and α-granule by TPO, with a 
likely role for the small GTPase RAP1 in this process. More specifically, based on our findings with both pharma-
cological inhibitors and genetic models, it is an increase in the activity of the p110β isoform of PI3K that mediates 
this TPO effect. In keeping with this observation, the phosphorylation of the PI3K effector Akt is considerably 
reduced by either treating platelets with TGX-221 or by knocking out p110β. However, residual phosphorylation 
when stimulating with TPO alone or TPO and a PAR agonist does remain. This contrasts with our findings with 
the pan-PI3K inhibitor wortmannin, indicating that TPO signals through multiple PI3K isoforms. Our findings 
suggest that c-MPL activation signals to a second PI3K isoform; p110γ. The evidence for this is that i) the p110γ 
inhibitor reduces TPO-mediated Akt phosphorylation and ii) the combination of p110β and p110γ inhibition 
ablates TPO-mediated Akt phosphorylation. Furthermore, deletion of the p110α isoform and p110δ inhibitors 
did not alter TPO-mediated phosphorylation of Akt (data not shown). The finding that TPO can signal and pro-
mote functional responses via p110γ is intriguing and unexpected. Activation of this PI3K isoform is typically 
thought to occur downstream of GPCRs, via the Gβγ subunits, with general opinion suggesting that p110γ is 
essential for GPCR but not tyrosine-kinase associated receptor, mediated activation of PI3K35,36. However, our 
data clearly shows that TPO, which signals through the cytokine receptor c-MPL, can enhance ERK phosphoryl-
ation and TxA2 synthesis through PI3K p110γ. Interestingly, there have been other reports of p110γ playing an 
important functional role downstream of other tyrosine-kinase associated receptors. A study by Alcázar et al.37, 
demonstrated that p110γ was activated by T cell receptor (TCR) ligation and that deletion of p110γ resulted in 
impairments in TCR signalling and T cell activation. Furthermore, Schmid et al.36, demonstrated a role for p110γ 
in regulating tumour inflammation initiated by a range of ligands coupling to receptor tyrosine kinases; VEGF-A, 
toll like/interleukin-1 receptors; IL-1β and cytokine receptors; IL-6.
Figure 7. Schematic summarising how PI3K p110β and p110γ regulate TPO-mediated amplification of platelet 
function. Stimulation of platelets with the c-MPL agonist TPO enhances (+) PAR-mediated integrin αIIbβ3 
activation and α-granule secretion. This enhancement occurs with concurrent increases in the GTP-loading 
of the small GTPase RAP1, phosphorylation of ERK1/2 and subsequent TxA2 formation. These processes are 
regulated by the activation of the PI3K isoforms p110β and p110γ. With our data suggesting that (a) PI3K 
p110β is the dominant isoform in regulating integrin αIIbβ3 activation and α-granule secretion whereas (b) PI3K 
p110γ is the dominant isoform in regulating the generation of TxA2.
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In addition to PI3K, TPO binding to c-MPL stimulates the activation of at least two MAPK pathways; ERK1/2 
and p38. This is mediated by the recruitment and tyrosine phosphorylation of Grb2, SHC, and SOS, and GTP 
loading of the small GTPase RAS. In haematopoietic stem cells and megakaryocytes this results in promotion of 
proliferation and differentiation38–40. However, in platelets TPO binding c-MPL doesn’t result in the phosphoryl-
ation of either ERK1/2 or p3841–43. This is despite platelets expressing the requisite upstream signalling molecules 
and TPO being able to stimulate the activation of RAS42. One explanation for this is that in platelets, RAS acti-
vation is not sufficient for ERK activation, as activation of PKC is required for the activation of ERK at the level 
of/upstream of MEK42. However, despite the inability of TPO to induce phosphorylation/activation of MAPKs, 
it can subtly enhance phosphorylation of p38 and induce a striking highly synergistic enhancement in ERK1/2 
phosphorylation. With the ability of TPO to induce these enhancements being not only dependent on the PI3K 
isoform p110β but also p110γ.
In human platelets, the MAPK family members have been implicated in regulating the production of TxA2; a 
prothrombotic agent which activates and amplifies platelet responses through the thromboxane receptors. TxA2 
is generated by thromboxane synthase from prostaglandin H2 (PGH2) which is itself generated from arachidonic 
acid by the aspirin target; cyclooxygenase. Previous work attributes the MAPK family members in being able to 
regulate TxA2 production through their ability to phosphorylate and therefore increase the catalytic activity of 
cytosolic phospholipase A2 (cPLA2). This enzyme in turn will hydrolyse various phospholipids, into arachidonic 
acid. Our and previous findings clearly demonstrate that TPO can markedly enhance TxA2 and, in agreement 
with van Willigen et al.,31 we believe this is mediated by the enhanced activation of ERK1/2. This is based on our 
finding that the MEK1/2 inhibitor PD184352, which blocks ERK1/2 phosphorylation/activation but not p38 
activity, ablates the synergistic component of TxA2 generation induced by TPO and SFLLRN. Furthermore, the 
p38 inhibitor; VX-702, which specifically blocked the phosphorylation of known p38 substrates, but not the phos-
phorylation of ERK1/2 or p38 itself, did not ablate the synergistic generation of TxA2.
In support of our findings regarding ERK1/2 phosphorylation, TxA2 generation induced by the combination 
of SFLLRN and TPO was drastically reduced by pan-PI3K inhibition. This reduction was an ablation of the 
synergistic component of TxA2 generation, as SFLLRN and TPO-mediated TxA2 generation in the presence of 
wortmannin was almost identical to TxA2 generation mediated by SFLLRN alone. In a further mirroring of our 
results on ERK1/2 phosphorylation, both the p110β and p110γ inhibitors could reduce the synergistic component 
and a further reduction was observed with combined inhibition. These data highlight and strengthen the idea that 
TPO through the PI3K isoforms; p110β and p110γ can synergistically increase SFLLRN-mediated activation of 
ERK1/2 which in turn leads to an enhancement in TxA2 production. Furthermore, this enhancement in TxA2 
can contribute to a pro-aggregatory response under conditions where cyclooxygenase is not directly inhibited.
We therefore conclude that TPO through the PI3K isoforms p110β and p110γ can enhance platelet activation 
through TxA2 independent and dependent pathways (Fig. 7). Therefore, under conditions where TPO levels or 
c-MPL signalling are pathophysiologically elevated, the pro-aggregatory response may be dampened by tradi-
tional anti-platelet therapies or ablated by PI3K inhibition.
Materials and Methods
Materials. Protease activated receptor 1 (PAR-1)-activating peptide (SFLLRN-NH2) was from Bachem 
(Bubendorf, Switzerland). Protease activated receptor 4 (PAR-4)-activating peptide (AYPGKF-NH2) was from 
PeptideSynthetics (Peptide Protein Research Ltd, Hampshire, UK). Recombinant human TPO and wortman-
nin were from Bio-Techne (Abingdon, UK). Recombinant murine thrombopoietin (TPO) was from PeproTech 
(London, UK). TGX-221, AS-252424, PD184352, IC-87114, PIK-75 and VX-702 were from Selleckchem 
(Stratech Scientific Ltd, Ely, UK). Mouse anti-human PAC-1 conjugated to FITC and mouse anti-human CD62P 
(AK-4) conjugated to PE were from BD Biosciences (Oxford, UK). Rat anti-mouse JON/A conjugated to PE and 
rat anti-mouse CD62P (Wug.E9) conjugated to FITC were from emfret ANALYTICS (Eibelstadt, DE). Phospho-
ERK1/2T202/Y204 (#9101), phospho-AktS473 (#4060), phospho-JAK2Y1007/1008 (#3771), phospho-STAT5α/βY694 
(#4322), phospho-p38T180/Y182 (#4511), phospho-MAPKAPK2T334 (#3007), phospho-HSP27S78(#2405), ERK1/2 
(#9102), Akt (#2920), and p110β (#3011) antibodies were from Cell Signaling Technology (New England Biolabs, 
Hitchin, UK). Talin (#SC7534), GAPDH (#SC25778) and RAP1 (#SC65) antibodies were from Santa Cruz 
Biotechnology (Insight Scientific, Middlesex, UK). Odyssey blocking buffer (TBS) was from LI-COR Biosciences 
(Cambridge, UK). Secondary antibodies were from Jackson ImmunoResearch (Stratech Scientific Ltd, Ely, UK). 
TxB2 ELISA kit was from Enzo Life Sciences (Exeter, UK). All other materials were from Sigma Aldrich (Poole, 
UK).
Human studies. Venous blood was drawn into a syringe containing 4% trisodium citrate (1:9, v/v). Blood 
was obtained with approval from the local Research Ethics Committee of the University of Bristol from healthy 
drug-free volunteers, who gave full informed consent in accordance with the Declaration of Helsinki.
Mouse Models. All animal studies were approved by the local research ethics committee at the University of 
Bristol, UK and mice were bred and maintained for this purpose under the UK Home Office licence PPL30/3445. 
Mice (8–24 weeks old) were sacrificed by rising CO2 inhalation, in accordance with Schedule 1 of the Animals 
(Scientific Procedures) Act (1986), and blood was drawn by cardiac puncture into a syringe containing 4% triso-
dium citrate (1:9, v/v). For transgenic experiments appropriate wild-type (WT) controls were used (strain, age 
and sex matched). p110α flox/flox:Pf4-Cre mice (C57BL/6) and p110β mice (mixed C57BL/6J x 129 Sv) have been 
previously described21,44.
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platelet Isolation. Washed human and mouse platelets were prepared as previously described21,45. Platelets 
were resuspended in HEPES–Tyrode’s buffer (pH 7.2; 145 mM NaCl, 5 mM KCl, 0.5 mM Na2HPO4, 1 mM MgSO4, 
10 mM HEPES), supplemented with 0.1% glucose (w/v), 10 μm indomethacin and 0.02 U mL−1 apyrase.
platelet Function Assays. Activation of integrin αIIbβ3 and α-granule secretion were assessed by flow 
cytometry as previously described using a BD AccuriTM C6 plus (BD Biosciences, Oxford, UK)46. For human 
platelets a FITC-conjugated antibody directed against the high affinity form of integrin αIIbβ3 (PAC-1) and 
PE-conjugated antibody for the α-granule marker CD62P (AK-4) were used. For mouse platelets a PE-conjugated 
antibody directed against the high affinity form of integrin αIIbβ3 (JON/A) and a FITC-conjugated antibody for 
the α-granule marker CD62P (Wug.E9) were used. For platelet aggregation, platelets (2 × 108/mL in the absence 
of indomethacin) were pre-incubated with inhibitors/TPO as indicated before agonist-stimulated aggregation 
was monitored using a CHRONO-LOG® Model 700 aggregometer at 37 °C, with continuous stirring at 1000 rpm. 
Data were recorded using Aggrolink Version 8 software (CHRONO-LOG®).
Protein Extraction and Immunoblotting. Washed platelets (4 × 108/mL) were stimulated as indicated 
and lysed directly in 4X NuPAGE sample buffer containing 0.5 M dithiothreitol (DTT). Proteins were resolved by 
electrophoresis as previously described45 and transferred onto polyvinylidene fluoride (PVDF) membranes. For 
some experiments, gels and membranes were cut into two parts to be probed separately with different primary 
antibodies47. Proteins were visualized by near-infrared detection using a LI-COR® Odyssey imaging system (pro-
viding a wide linear dynamic range) unless indicated otherwise. LI-COR® Image Studio (LI-COR®, Cambridge, 
UK) was used to create final images, the software analysis options only affect how raw data pixels are mapped to 
the screen and does not alter the experimental data. LI-COR® Image Studio (LI-COR®, Cambridge, UK) was 
used to quantify bands. Bands were defined using the rectangle shape tool to obtain fluorescence values and 
median local background (intensity of pixels in a border around the shape) was automatically subtracted.
RAP1 Activation Assay. Was performed using the Ral guanine nucleotide dissociation stimulator 
RAP-binding domain protein (GST-RALGDS-RBD) as previously described13.
txA2 Generation. TxA2 generation was assessed by measuring TxB2 in platelet supernatants using a com-
mercially available colorimetric ELISA kit (Enzo Life Sciences, Exeter, UK) as previously described48. Briefly, 
platelets (4 × 108/ml in the absence of indomethacin) were stimulated as indicated before addition of 5 mM ethyl-
enediaminetetraacetic acid and 200 μM indomethacin. Platelets were pelleted (4 min, 12,000 × g) and supernatant 
collected for analysis.
Data Analysis. Data were analysed and fitted using GraphPad Prism 7 software. All data are presented as 
the mean ± s.e.m of at least three independent observations. Concentration-response curves were fitted with a 
four-parameter logistic equation.
= + − + .− ∗Y Bottom (Top Bottom)/(1 10 )EC X((Log 50 ) HillSlope)
Concentration-response curves from different donors were pooled after normalising them to the maximal 
response (Top) obtained in the vehicle-control samples. Data presented with statistical analysis were tested as 
indicated in the figure legends (GraphPad Prism 7).
Data Availability
The datasets generated and analysed during the current study are available on reasonable request.
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